Observe Medical ASA – Approval and publication of listing prospectus
Observe Medical ASA, 1 November 2019: Reference is made to Navamedic ASA's ("NAVA") and Observe Medical ASA's ("Observe Medical") stock exchange announcements dated 30 October 2019 and 31 October 2019, regarding Oslo Børs' approval of Observe Medical's application for listing of its shares on Oslo Axess (the "Listing") and the completion of the demerger of NAVA, respectively.
The prospectus for the Listing (the "Prospectus") was approved by the Financial Supervisory Authority of Norway today, on 1 November 2019. The Prospectus has been published today and is available at www.observemedical.com. Hard copies of the Prospectus may be obtained by contacting Observe Medical.
Observe Medical's shares will be listed on Oslo Axess on Monday 4 November 2019.
For further information, please contact:
Ole Henrik Eriksen, interim CEO of Observe Medical
Mobile: +47 400 62 000
About Observe Medical ASA:
Observe Medical develops and markets innovative hospital products that contribute to increased patient safety and a more efficient care system. The Company's headquarter is in Oslo and its operations are based out of Sweden. Observe Medical's initial product was Sippi®, the only digital urine meter with wireless data transfer to patient data management systems, which also prevents bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is CE marked and is currently being launched at selected hospitals in the Nordics and Germany.